Search
Lepunafusp alfa
go.drugbank.com/drugs/DB19011InvestigationalLepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).
Canis lupus familiaris skin
go.drugbank.com/drugs/DB10409ApprovedCanis lupus familiaris skin allergenic extract is used in allergenic testing.
Cedar oil
go.drugbank.com/drugs/DB10917ApprovedCedar oil (Juniperus virginiana) allergenic extract is used in allergenic testing.
Trevogrumab
go.drugbank.com/drugs/DB15159Investigationaland Healthy Adult Men). … Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women
PPI-1019
go.drugbank.com/drugs/DB05832InvestigationalApan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Cetrelimab
go.drugbank.com/drugs/DB15421Investigational)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers). … Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD
Equilenin
go.drugbank.com/drugs/DB03515ExperimentalEquilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.
Dacetuzumab
go.drugbank.com/drugs/DB12589InvestigationalIt is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse.
99mTc-glucarate
go.drugbank.com/drugs/DB05810Investigational99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients